Lilly beats forecasts, helped by cost controls

July 24 Thu Jul 24, 2014 6:48am EDT

July 24 (Reuters) - Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but overall results beat forecasts, helped by cost controls.

The U.S. drugmaker on Thursday said it earned $734 million, or 68 cents per share, in the second quarter. That compared with $1.21 billion, or $1.11 per share, in the year-ago period, when the company took charges for closing a distribution center and other costs.

Excluding special items, Lilly earned 68 cents per share. Analysts, on average, expected $0.65 per share, according to Thomson Reuters I/B/E/S.

(Reporting by Ransdell Pierson, Editing by Franklin Paul)

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article